Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.
It could be fantastic and cover all Coronavirus` maybe preventing the next Mers (case fatality rate of 32.7%) or it may fail or be somewhere in between.
the nucleocapsid (N) protein, which makes up the bulk of the virus particle, is "highly conserved" – meaning much less likely to mutate.
“We don’t necessarily claim it will be a pan-coronavirus vaccine, but it has got the potential to be so simply because of where it is targeted," Dr Gillies O’Bryan-Tear, the chief medical officer of the immunology company Scancell which collaborates with the University of Nottingham, told the Daily Telegraph.
Dr O'Bryan-Tear said that the vaccine candidate needed a big pharmaceutical partner and hundreds of millions of pounds to put it through the clinical trials process.
If this funding is in place then it could be developed within a year.
"There is no reason why, if we get a partner, we shouldn't be able to do it as quickly as the others have done it," Dr O'Bryan-Tear told the Telegraph.
Good to hear that Chelsea.
CNBC's Closing Bell
@CNBCClosingBell
· 13h
Could COVID continue to mutate into more lethal strains that could evade the vaccines?
"It's possible," says @scottgottliebmd. "This virus is gonna become endemic. It's gonna be with us probably for eternity. It's gonna evolve slowly over time...we'll have to adapt the vaccine."
https://twitter.com/BLLPHD/status/1416180363873902597?s=20
Ray, wasn`t it just Enolase 241 peptide that caused the major problem? They resolved that and probably now have it manufactured ready for the trial. I`m sure that they have learned a lot from that for Modi-2 and Mod-3
https://youtu.be/VEbic53pJ_A?t=714
http://www.meetingsmanagement.co.uk/index.php?option=com_content&view=article&id=597&Itemid=1086
SESSION 4:SESSION 6:
DELIVERY,SESSION 8:
DEVICES
MICRONEEDLE PATCHES,SESSION 5:
MICROARRAY PATCHES
‘Targeting citrullinated vimentin and enolase with cytotoxic CD4 T cells, relies upon MHC-II expression by tumors, reduces myeloid suppressor cells and directly kills tumor cells’
Victoria A. Brentville1, Rachael L. Metheringham1, Ian Daniels1, Suha Atabani2, Peter Symonds1, Katherine W. Cook1, Ruhul Choudhury1, Poonam Vaghela1, Mohamed Gijon1, Ghislaine Meiners3, Willem-Jan Krebber3, Cornelis J. Melief3,4 and Lindy G. Durrant1,2
(1 Scancell Limited Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK; 2 Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK)
Thanks Ratcliff. I see Zakari as a positive move. We will be told what it is for soon enough I reckon. They probably can not disclose for numerous reasons atm.
Scancell Holdings Plc, (AIM:SCLP), today announces the appointment of John Chiplin as Non-Executive Chairman, succeeding current Chairman David Evans who has offered his resignation to the Board in line with his personal decision to reduce his number of Non-Executive Chairman roles. John Chiplin will take on this position with immediate effect.
John Chiplin joined the Board of Scancell as a senior Non-Executive Director on 14 October 2015. John is based in the United States and his appointment as Chairman is in line with the Company’s strategy of increased focus in the US.
Probably would be higher than £10,000 per patient actually.
https://www.evidence.nhs.uk/document?id=1968626&returnUrl=search%3Fpa%3D14%26q%3Ddrug%2Bprices&q=drug+prices
The top two lead mAbs, FG27 and FG88, could potentially treat 214,500 and 421,500 patients per annum based upon the % of tumours that express the target antigen. These are patients who currently have failed all other therapies and die of their disease. If we assume market penetration of 50% and a treatment price of £10,000 per patient this is a potential market of £1-2 billion.
The radio silence is very encouraging, must be plenty happening.
If we can get the mABS through phase I then they could be very valuable. $1 Billion deals for stage II ready monoclonal antibodies. Latest one 1.2 billion US dollars, including 100 million dollars in upfront and near-term clinical milestone payments. PRX004 is an investigational humanised monoclonal antibody
Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy.
https://www.scancell.co.uk/Data/Sites/1/media/docspres/2811-bsi-liverpool.pdf
https://youtu.be/VEbic53pJ_A?t=1473
I would imagine SCLP can produce even more going by their history
https://www.scancell.co.uk/scancell-sells-antibody-pipeline-to-peptech
Scancell sells antibody pipeline to Peptech
https://www.scancell.co.uk/scancell-sells-antibody-pipeline-to-peptech
The estimates for two of our mABS is;
The top two lead mAbs, FG27 and FG88, could potentially treat 214,500 and 421,500 patients per annum based upon the % of tumours that express the target antigen. These are patients who currently have failed all other therapies and die of their disease. If we assume market penetration of 50% and a treatment price of £10,000 per patient this is a potential market of £1-2 billion.
https://gtr.ukri.org/projects?ref=MR%2FM015564%2F1
PRX004 is an investigational humanised monoclonal antibody
Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy
https://www.globenewswire.com/news-release/2021/07/12/2261050/24041/en/Prothena-and-Novo-Nordisk-Announce-Acquisition-Agreement-for-Prothena-s-ATTR-Amyloidosis-Programme.html
Thanks Loch,
convertible loan note, The CLN will carry a modest interest rate of 3% and will not be convertible (at 13p) for two years unless Scancell is subject to a takeover or a NASDAQ listing.
Importantly, Redmile is known as an active and supportive shareholder that prefers value to be generated in-house rather than partnered too early. It is worth noting that Redmile is also invested in Redx Pharma (September 2020 Initiation).
Redx Pharma set to be acquired by Redmile
https://www.ns-healthcare.com/news/redx-pharma-redmile/
WTP, I am no expert in this field but if they list on Nasdaq as Zakari, Balerno seems to think it would avoid a mandatory bid by Redmile.
I was just wondering what everyone else thought.
The only other reason I can see would be to perhaps put Covidity or something into Zakari.
Takeover Code
Conversion of all existing CLNs held by the Redmile Funds at this time would result in a potential holding of
c.43%. The ability of the Redmile Funds to increase its voting rights in the Company to 30% or more, however, is
subject to the constraints of the Takeover Code.
As such, should the acquisition of ordinary shares or interests therein increase the aggregate voting rights of the
acquirer (and its concert parties) to this figure or more, the acquirer and, depending on circumstances, its concert
parties would be required (except with the consent of the Takeover Panel) to make a cash offer for the outstanding
shares in the Company at a price not less than the highest price paid for interests in shares by the acquirer or its
concert parties during the previous 12 months.
Strategy post-Redmile funding initiative
Redmile recognised the broad utility of Scancell’s technologies and development pipeline. It also appears to wish
to take advantage of an apparent ‘scientific arbitrage’ opportunity that seemingly has been created between the US
and Europe, in terms of recognising the different levels of scientific value allocated to innovative drug development
technologies/initiatives and the teams driving/supporting them in different geographical locations. Within this, it
recognised a major and continuing drag on successful development and its associated commercialisation due to
the lack of adequate and immediately funding, perhaps resulting from a relatively pedantic ‘drip-feed’ European
approach to extending/progressing necessarily costly clinical and/or tech-intensive projects. Having selected such
‘winners’, the contrasting ‘US approach’ adopted by Redmile instead, is to inject significant ‘transformational’ cash
funding (in either straight equity, CLNs or a mix of the two) that can be rapidly put to work in order to resource and
accelerate existing programmes, while also seeking to seize opportunities unique technologies might present and
in tandem broadening pipelines sufficiently to capture a larger proportion of the inherent value, rather than
externalise the assets too early through royalty or milestone-based sales to larger, better-resourced development
partnerships.
This was an interesting view from Balerno;
23-06-2021
balerno1
The formation of the subsidiary and potential launch into NASDAQ will avoid the funder clause which will trigger a takeover bid. Great move!
https://find-and-update.company-information.service.gov.uk/company/13408042/officers
Initial data maybe Q2 or Q3 2022 if we get started by the Autumn I am guessing?
(TPOPE back in November)
Taking this together with a successful regulatory Scientific Advice meeting held with the UK MHRA in February
2020, Scancell now anticipates a relatively smooth application for EU clinical trials once manufacturing process is
completed. While continuing to progress the necessary processes and documentation required for regulatory
submission, a Clinical Trial Application (‘CTA’) is targeted before end-2020, with a view to start the planned clinical
study in the UK in H1 2021.
The molecule’s proposed first study in humans has been designed on two initial cohorts to explore low and high
conjugate doses with a follow-on study enrolling four tumour-specific expansion cohorts. If selected for expansion,
HPV-negative head and neck patients will be treated with Opdivo (nivolumab) and Modi-1. Monotherapy cohorts
(TNBC, ovarian and renal) Simon 2-stage design requires =19% of patients to respond for further investigation, while
combination therapy (HPV-ve HNSCC) Simon 2-stage design requires =28% of patients to respond for further
investigation.
Based on these timelines, assuming dose escalation recruitment complete within six months, interim data might
be available during H2 2021 (probably including safety information and potentially also early efficacy indicators); a
more extensive interim trial result read out might then be seen during 2022
https://www.turnerpope.com/wp-content/uploads/2020/12/Scancell_Holdings_plc_19_11_2020_FINAL_BGv3.pdf
Fingers crossed.
Scancell could even become a lead player in the landscape, if Professor Durrant’s optimism is well-placed.
“SCIB1 is in the clinic and it’s working,” she said. “Moditope is a different way of looking at things. In animals, it’s been amazing, but it needs to work in humans. It could be huge, it could be small – hopefully it’s significant.”
https://www.thepharmaletter.com/article/i-o-is-probably-under-hyped-says-scancell-chairman
Thanks Burble,
it is exciting to see Moditope close to trial.
. The action of Moditope-induced CD4 T-cells could potentially change
the tumour microenvironment, notably through the secretion of IFN-? and the
resultant inflammation, thereby converting tumours that are currently considered
“cold” into “hot” ones, and therefore become responsive to checkpoint inhibitors
and a cytotoxic CD8 T-cell response.
https://www.scancell.co.uk/Data/Sites/1/media/docspres/scancell-outlook-resons-to-be-cheerful-110520.pdf
Examples of therapeutic approaches to drive T cells into tumors
Main mechanisms Therapeutic approaches References
Promotes T-cell priming Immune adjuvants (TLR agonists, STING agonists) [102, 105]
Oncolytic viruses [109, 111]
Chemotherapy and radiotherapy [114, 119]
Epigenetic modification inhibitors (DNMT inhibitor, HDAC inhibitor, EZH2 inhibitor) [140-142]
Metabolic intervention [94, 97, 99]
Local thermal ablation therapy (Radiofrequency ablation) [123]
Photothermal therapy and photodynamic therapy [161-163]
Magnetic hyperthermia [165, 166]
High-intensity focused ultrasound [167, 168]
Promotes T-cell expansion Adoptive cellular therapy (TILs, CAR-T cells) [34, 125, 126]
Vaccines [129]
Promotes T-cell trafficking and infiltration Oncogenic pathway inhibitors [38, 130, 138]
Epigenetic modification inhibitors [48, 49, 51]
Antiangiogenic therapy (anti-VEGF) [146]
TGFß inhibitors [72, 73, 148]
CXCR4 inhibitors
https://www.thno.org/v11p5365.htm
https://www.prnewswire.com/news-releases/oncosec-enters-into-a-collaboration-agreement-with-merck-for-a-pivotal-global-phase-3-study-keynote-c87-of-tavo-combined-with-keytruda-for-late-stage-metastatic-melanoma-301325841.html
a DNA plasmid-based interleukin-12 (IL-12), with an intra-tumoral electroporation gene delivery platform to achieve endogenous IL-12 production in the tumor microenvironment that enables the immune system to target and attack tumors throughout the body